Pacira BioSciences, Inc. (NASDAQ: PCRX) is a Healthcare company (Drug Manufacturers - Specialty & Generic) with a market capitalization of $1.5B. The Maz Rating grades it against the other companies in its sector.
Pacira BioSciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $36.48, Pacira BioSciences, Inc. trades at 38.3x trailing earnings, 2.0x sales and 2.0x book value, with an EV/EBITDA of 11.8. Over the last twelve months it generated about $743M of revenue and $38M of net income. It runs a gross margin of 78.7%, an operating margin of 4.6% and a net margin of 5.1%. It shows return on equity of 5.5%, return on invested capital of 3.2% and a free cash flow yield of 11.6%. On the balance sheet: a debt-to-equity ratio of 0.48 and a current ratio of 4.68. Over the past 52 weeks the share price ranged from $18.80 to $36.67, with a beta of 0.25.
Pacira BioSciences, Inc. does not currently pay a dividend.
36 Wall Street analyst ratings cover the stock: 11 Buy, 22 Hold and 3 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.